• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration.使用胰高血糖素样肽-1受体激动剂相关的急性胆囊炎病例已上报美国食品药品监督管理局。
JAMA Intern Med. 2022 Oct 1;182(10):1104-1106. doi: 10.1001/jamainternmed.2022.3810.
2
Cross-Sectional Analysis of Adverse Dermatologic Events Reported to the FDA After Use of GLP-1 Agonists.使用GLP-1激动剂后向美国食品药品监督管理局报告的不良皮肤事件的横断面分析
J Drugs Dermatol. 2024 Sep 1;23(9):e181-e182.
3
New Injectable Agents for the Treatment of Type 2 Diabetes Part 2-Glucagon-Like Peptide-1 (GLP-1) Agonists.新型 2 型糖尿病治疗药物 第 2 部分：胰高血糖素样肽-1（GLP-1）激动剂。
Am J Med. 2018 Nov;131(11):1304-1306. doi: 10.1016/j.amjmed.2018.05.043. Epub 2018 Jul 2.
4
Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.胰高血糖素样肽-1及其受体激动剂：它们在2型糖尿病管理中的作用。
Diabetes Metab Syndr. 2017 Jul-Sep;11(3):225-230. doi: 10.1016/j.dsx.2016.09.003. Epub 2016 Sep 15.
5
Delivery Device Patents on GLP-1 Receptor Agonists.GLP-1受体激动剂的给药装置专利。
JAMA. 2024 Mar 5;331(9):794-796. doi: 10.1001/jama.2024.0919.
6
Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study.胰高血糖素样肽-1 受体激动剂与 2 型糖尿病患者胆道相关疾病的相关性：一项全国性队列研究。
Pharmacotherapy. 2022 Jun;42(6):483-494. doi: 10.1002/phar.2688. Epub 2022 May 17.
7
Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.不同 GLP-1 受体激动剂与胃肠道不良反应的关联性：基于 FDA 不良事件报告系统数据库的真实世界药物不良反应比例性研究。
Front Endocrinol (Lausanne). 2022 Dec 7;13:1043789. doi: 10.3389/fendo.2022.1043789. eCollection 2022.
8
Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy.比较使用单个术语和复合术语评估药物不良事件的不均衡性：以胰高血糖素样肽-1受体激动剂和糖尿病视网膜病变为重点。
Expert Opin Drug Saf. 2021 Apr;20(4):475-480. doi: 10.1080/14740338.2021.1887136. Epub 2021 Mar 26.
9
Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists.心脏病专家开具胰高血糖素样肽-1受体激动剂的处方情况。
J Am Coll Cardiol. 2019 Apr 2;73(12):1596-1598. doi: 10.1016/j.jacc.2019.01.029.
10
No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials.GLP-1 受体激动剂治疗后无胰腺安全性担忧：心血管结局试验的汇总分析。
Diabetes Metab Res Rev. 2018 Nov;34(8):e3061. doi: 10.1002/dmrr.3061. Epub 2018 Sep 14.

引用本文的文献

1
Glucagon-like peptide-1 receptor agonists: Evolution, gastrointestinal adverse effects, and future directions.胰高血糖素样肽-1受体激动剂：演变、胃肠道不良反应及未来方向。
World J Gastrointest Pharmacol Ther. 2025 Sep 5;16(3):107148. doi: 10.4292/wjgpt.v16.i3.107148.
2
Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database.胰高血糖素样肽-1受体激动剂诱发的胆囊炎和胆石症：一项使用FAERS数据库的真实世界药物警戒分析
Front Pharmacol. 2025 Jul 8;16:1557691. doi: 10.3389/fphar.2025.1557691. eCollection 2025.
3
Evolving incretin-based therapies in Japan: optimizing treatment strategies for diverse clinical and socioeconomical profiles in type 2 diabetes.日本基于肠促胰岛素疗法的发展：针对2型糖尿病不同临床和社会经济状况优化治疗策略
Diabetol Int. 2025 May 15;16(3):457-468. doi: 10.1007/s13340-025-00818-w. eCollection 2025 Jul.
4
Incretin-based drugs and the risk of gallbladder or biliary tract diseases among patients with type 2 diabetes across categories of body mass index: a nationwide cohort study.基于肠促胰岛素的药物与不同体重指数类别2型糖尿病患者胆囊或胆道疾病风险：一项全国性队列研究
Lancet Reg Health West Pac. 2025 Mar 10;56:101242. doi: 10.1016/j.lanwpc.2024.101242. eCollection 2025 Mar.
5
The Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Acute Cholecystitis After a Routine Colonoscopy: A Case Report.胰高血糖素样肽-1（GLP-1）受体激动剂在常规结肠镜检查后急性胆囊炎中的作用：一例报告
Cureus. 2025 Feb 16;17(2):e79105. doi: 10.7759/cureus.79105. eCollection 2025 Feb.
6
Semaglutide: Double-edged Sword with Risks and Benefits.司美格鲁肽：利弊兼具的双刃剑。
Arch Intern Med Res. 2025;8(1):1-13. doi: 10.26502/aimr.0189. Epub 2025 Jan 10.
7
The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension.胰高血糖素样肽-1受体激动剂（GLP1-RAs）在代谢综合征高血压患者管理中的作用：韩国高血压学会立场文件
Clin Hypertens. 2024 Sep 1;30(1):24. doi: 10.1186/s40885-024-00279-4.
8
Hemiplegic Migraines Exacerbated using an Injectable GLP-1 Agonist for Weight Loss.使用注射用GLP-1激动剂减肥加重偏瘫性偏头痛。
Acta Sci Neurol. 2024 May;7(5):12-18. doi: 10.31080/asne.2024.07.0731. Epub 2024 Apr 19.
9
Dipeptidyl Peptidase-4 Inhibitors and the Risk of Gallbladder and Bile Duct Disease Among Patients with Type 2 Diabetes: A Population-Based Cohort Study.二肽基肽酶-4 抑制剂与 2 型糖尿病患者胆囊和胆管疾病风险：一项基于人群的队列研究。
Drug Saf. 2024 Aug;47(8):759-769. doi: 10.1007/s40264-024-01434-4. Epub 2024 May 8.
10
Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities.从青年到老年肥胖常见心脏代谢并发症的脂肪中心起源：病理生理学与新的治疗机遇
Front Med (Lausanne). 2024 Apr 8;11:1365183. doi: 10.3389/fmed.2024.1365183. eCollection 2024.

Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration.

作者信息

Woronow Daniel, Chamberlain Christine, Niak Ali, Avigan Mark, Houstoun Monika, Kortepeter Cindy

机构信息

Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, Division of Pharmacovigilance, US Food and Drug Administration, Silver Spring, Maryland.

Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, US Food and Drug Administration, Silver Spring, Maryland.

出版信息

JAMA Intern Med. 2022 Oct 1;182(10):1104-1106. doi: 10.1001/jamainternmed.2022.3810.

DOI:10.1001/jamainternmed.2022.3810
PMID:36036939
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9425280/
Abstract
摘要